Health · Pharma & Biotech · 5 hrs ago
Zealand Pharma signs deal worth up to $1.3 billion for AI-designed treatments
Zealand Pharma has signed a deal worth up to $1.3 billion with Generate Biomedicines.
The companies plan to use AI technology to develop protein-based treatments.
The treatments are intended for obesity and other metabolic diseases.
Zealand Pharma is a pharmaceutical company, and Generate Biomedicines is providing its AI technology for the work.
The deal brings together drug development and AI to pursue new treatment options.
The companies have not announced a timeline for the work.
Zealand Pharma said it will develop protein-based treatments for obesity and other metabolic diseases with help from Generate Biomedicines’ AI technology.
The deal is worth up to $1.3 billion.
The treatments are to be designed using Generate Biomedicines’ technology.
The announcement was reported on October 14, 2026.
- Who
- Zealand Pharma and Generate Biomedicines.
- What
- They will work on protein-based treatments for obesity and other metabolic diseases. The deal is worth up to $1.3 billion.
- When
- Zealand Pharma said Tuesday; the article was published October 14, 2026.
- Where
- Not stated.
- Why
- To develop treatments for obesity and other metabolic diseases with the help of AI technology.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Deal value
- Up to $1.3 billion
- Companies
- Zealand Pharma and Generate Biomedicines
- Treatment type
- Protein-based treatments
- Target conditions
- Obesity and other metabolic diseases
- Technology
- Generate Biomedicines’ AI technology